RTCS Differentiation

RT Cardiac Systems Differentiation

RTCS has two major advantages relative to our competitors, who are developing next-generation percutaneous, mechanical circulatory systems (pMCS). The first is our novel technology that improves hemodynamic performance with the potential to reduce adverse events. The second is our blood pump development expertise and pre-clinical development that led to the second commercially successful chronic MCS device and company, HeartWare HVAD.

The RTCS technology utilizes a short flexible driveshaft that connects the next generation axial flow pump with state of the art, implanted motor. Our projected advantages include

  • Increased circulatory support and efficiency potentially reducing hemolysis

  • Device flexibility with the short flexible drive shaft improves ventricle compatibility

  • Sealed driveline system not requiring an external lubrication system found in the current market leader devices

  • Flexible, small diameter electrical conductor only driveline could translate into lower access site vascular complications

These potential advantages need to be confirmed through clinical trials, and our team’s experience in technical risk reduction and clinical collaboration puts RTCS into a position to be a leading competitor in the PMCS market.